Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

413 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program.
Pulley JM, Jerome RN, Ogletree ML, Bernard GR, Lavieri RR, Zaleski NM, Hong CC, Shirey-Rice JK, Arteaga CL, Mayer IA, Holroyd KJ, Cook RS. Pulley JM, et al. Among authors: arteaga cl. Target Oncol. 2018 Feb;13(1):61-68. doi: 10.1007/s11523-017-0542-1. Target Oncol. 2018. PMID: 29218624 Free PMC article. Review.
Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL. Guix M, et al. Among authors: arteaga cl. J Clin Oncol. 2008 Feb 20;26(6):897-906. doi: 10.1200/JCO.2007.13.5939. Epub 2008 Jan 7. J Clin Oncol. 2008. PMID: 18180460 Clinical Trial.
Evaluation of biological agents targeted at early-stage disease.
Guix M, Mayer IA, Meszoely IM, Arteaga CL. Guix M, et al. Among authors: arteaga cl. Breast Cancer Res. 2008;10 Suppl 4(Suppl 4):S25. doi: 10.1186/bcr2185. Epub 2008 Dec 18. Breast Cancer Res. 2008. PMID: 19128439 Free PMC article. No abstract available.
Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.
Miller TW, Forbes JT, Shah C, Wyatt SK, Manning HC, Olivares MG, Sanchez V, Dugger TC, de Matos Granja N, Narasanna A, Cook RS, Kennedy JP, Lindsley CW, Arteaga CL. Miller TW, et al. Among authors: arteaga cl. Clin Cancer Res. 2009 Dec 1;15(23):7266-76. doi: 10.1158/1078-0432.CCR-09-1665. Epub 2009 Nov 24. Clin Cancer Res. 2009. PMID: 19934303 Free PMC article.
Does lapatinib work against HER2-negative breast cancers?
Mayer IA, Arteaga CL. Mayer IA, et al. Among authors: arteaga cl. Clin Cancer Res. 2010 Mar 1;16(5):1355-7. doi: 10.1158/1078-0432.CCR-09-3223. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179241 Free PMC article. Review.
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.
Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL. Garrett JT, et al. Among authors: arteaga cl. Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5021-6. doi: 10.1073/pnas.1016140108. Epub 2011 Mar 8. Proc Natl Acad Sci U S A. 2011. PMID: 21385943 Free PMC article.
ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis.
Cook RS, Garrett JT, Sánchez V, Stanford JC, Young C, Chakrabarty A, Rinehart C, Zhang Y, Wu Y, Greenberger L, Horak ID, Arteaga CL. Cook RS, et al. Among authors: arteaga cl. Cancer Res. 2011 Jun 1;71(11):3941-51. doi: 10.1158/0008-5472.CAN-10-3775. Epub 2011 Apr 11. Cancer Res. 2011. PMID: 21482676 Free PMC article.
413 results